Stock Analysis on Net
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

Paying users zone. Data is hidden behind: .


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Cash Flow Statement
Quarterly Data

Beginner level

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company’s balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Biogen Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel LibreOffice Calc
3 months ended: Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Net income
Depreciation, amortization and impairments
Acquired in-process research and development
Share-based compensation
Gain on interest rate swap
Contingent consideration
Loss on divestiture of Hillerød, Denmark manufacturing operations
Deferred income taxes
Unrealized (gain) loss on strategic investments
Loss on equity method investment
Other
Accounts receivable
Due from anti-CD20 therapeutic programs
Inventory
Accrued expenses and other current liabilities
Income tax assets and liabilities
Other changes in operating assets and liabilities, net
Changes in operating assets and liabilities, net
Adjustments to reconcile net income to net cash flows from operating activities
Net cash flows provided by operating activities
Proceeds from sales and maturities of marketable securities
Purchases of marketable securities
Contingent consideration paid related to Fumapharm AG acquisition
Acquisition of Nightstar Therapeutics plc, net of cash acquired
Purchase of Sangamo Therapeutics, Inc. stock
Proceeds from divestiture of Hillerød, Denmark manufacturing operations
Purchases of property, plant and equipment
Acquired in-process research and development
Acquisitions of intangible assets
Proceeds from settlement of net investment hedge
Purchase of Ionis Pharmaceuticals, Inc. stock
Proceeds from sales of strategic investments
Investment in Samsung Bioepis
Acquisitions of business, net of cash acquired
Other
Net cash flows (used in) provided by investing activities
Purchases of treasury stock
Payments related to issuance of stock for share-based compensation arrangements, net
Proceeds from borrowings
Repayment of borrowings
Cash proceeds from settlement of swap
Net distribution to noncontrolling interest
Net cash contribution to Bioverativ Inc.
Contingent consideration payments
Excess tax benefit from share-based awards
Other
Net cash flows provided by (used in) financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents

Based on: 10-Q (filing date: 2020-07-22), 10-Q (filing date: 2020-04-23), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-22), 10-Q (filing date: 2019-07-24), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-06), 10-Q (filing date: 2018-10-23), 10-Q (filing date: 2018-07-24), 10-Q (filing date: 2018-04-24), 10-K (filing date: 2018-02-01), 10-Q (filing date: 2017-10-24), 10-Q (filing date: 2017-07-25), 10-Q (filing date: 2017-04-25), 10-K (filing date: 2017-02-02), 10-Q (filing date: 2016-10-26), 10-Q (filing date: 2016-07-21), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-03), 10-Q (filing date: 2015-10-21), 10-Q (filing date: 2015-07-24), 10-Q (filing date: 2015-04-24).

Cash flow statement item Description The company
Net cash flows provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Biogen Inc.’s net cash flows provided by operating activities decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 not reaching Q4 2019 level.
Net cash flows (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Biogen Inc.’s net cash flows (used in) provided by investing activities decreased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Net cash flows provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Biogen Inc.’s net cash flows provided by (used in) financing activities decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.